Latest Breaking News On - Professor jing zhang - Page 1 : comparemela.com

Zenshine Pharmaceuticals ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults

Zenshine Pharmaceuticals ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jinfu yangWenhong zhangNational centerFudan universityZenshine pharmaceuticals co ltdZenshine pharmaceuticalsFirst infection collaboration forumChinese national centerInfectious diseasesProfessor jing zhangHuashan hospital

China NMPA Approves NUZYRA® as a Category 1 Innovative Drug

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential.

United statesHong kongJing zhangUnited kingdomHarald reinhartHaihui huangZai labDrug administrationParatek pharmaceuticals incZai lab limitedDrug clinical trial centerExchange commissionChina national medical products administrationResearch instituteFudan university affiliated huashan hospitalInfectious diseases at zai lab

China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline

United statesHong kongJing zhangUnited kingdomHarald reinhartRon aldridgeAlina zhangHaihui huangDanielle halstrom xiaoyu chenZai labDrug administrationParatek pharmaceuticals incZai lab limitedDrug clinical trial centerExchange commissionChina national medical products administration